Omalizumab in patients with NSAIDs-exacerbated respiratory disease | Zendy

Ulrike FörsterRuhrmann | Zendy; Dafni Stergioudi | Zendy; Greta Pierchalla | Zendy; Joachim W. Fluhr | Zendy; KarlChristian Bergmann | Zendy; Heidi Olze | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Omalizumab in patients with NSAIDs-exacerbated respiratory disease

Author(s) -

Ulrike FörsterRuhrmann,

Dafni Stergioudi,

Greta Pierchalla,

Joachim W. Fluhr,

KarlChristian Bergmann,

Heidi Olze

Publication year - 2020

Publication title -

rhinology journal

Language(s) - English

Resource type - Journals

eISSN - 1996-8604

pISSN - 0300-0729

DOI - 10.4193/rhin19.318

Subject(s) - medicine , omalizumab , nasal polyps , asthma , sinusitis , gastroenterology , surgery , immunoglobulin e , antibody , immunology

The association of acetylsalicylic acid (ASA) intolerance, chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, or chronic urticaria is known as NSAID-exacerbated respiratory disease (N-ERD). N-ERD patients often suffer from recurrent nasal polyps, severe asthma or also from urticaria. The aim of the present study was to retrospectively analyze the clinical efficacy of anti-IgE antibody treatment with omalizumab in patients with confirmed N-ERD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research